International Journal of Bioinformatics and Biomedical Engineering
Articles Information
International Journal of Bioinformatics and Biomedical Engineering, Vol.3, No.3, May 2017, Pub. Date: Nov. 1, 2017
Comparison of Some Complication in β-Thalassemia Patients with Control Group
Pages: 20-26 Views: 51 Downloads: 54
Authors
[01] Amad Mohamed Saleh Jubrail, Department of Biology, College of Science, University of Duhok, Duhok, Iraq.
[02] Ghorbat Saleh Ali, Department of Biology, College of Science, University of Duhok, Duhok, Iraq.
[03] Malika Kassim Najeeb, Department of Biology, College of Science, University of Duhok, Duhok, Iraq.
Abstract
Beta thalassemia is a type of inherited blood disorder, characterized by reduced or absent synthesis of the beta chains. Currently, blood transfusion and sufficient of iron chelation therapy are important factors for treatment and follow up of thalassemia patients. Fortunately, high blood transfusion patients causes progressive iron overload. Consequently, the excess iron is deposited as hemosiderin and ferritin tissues and multiple complications such as liver, heart, endocrine dysfunction like hypothyroidism and hypogonadism. To comparison the serum T4, TSH, estradiol, testosterone and vitamin D levels of ß-Thalassemia major with control group. Thirty-eight patients with ß-Thalassemia major with mean age of 14.08± 3.02 years were studied. All cases received blood transfusion and given chelation therapy. Also, thirty-eight healthy persons with mean age of 13.34 ± 2.74 years participated as the control group. In comparison of β- thalassemia major patients with control group, the results indicated the serum level of FT4 hormone did not differ significantly between the two groups whereas TSH (3.86 ± 2.7 1 µIU/ml) in the β-thalassemia major patients were increased significantly (p<0.05) that compared with control group (2.72 ± 1.01 µIU/ml) and 23.68% (9/38) had subclinical hypothyroidism. Estradiol level in β-thalassemia major patients was significantly different (P< 0.001) from control group. The level of estradiol in the patients (30.60 ± 14.68 pg/ml) is high significant (p< 0.01) decreased that compared with level in control group (13.83 ± 9.06 pg/ml) more than 13years. Mean level of testosterone was highly significantly lower in β-thalassemia major patients than control group (p< 0.001). The mean of testosterone level was 1.22 ± 0.83 ng/ml in β-thalassemia patients and 3.71 ± 1.32ng/ml in control group more than 14 year. Mean of 25-hydroxy vitamin D level (11.11 ± 4.36 ng/ml) in patients was significantly lower than control group (14.03 ± 5.96 ng/ml). These results indicate high prevalence vitamin D deficiency, hypothyroidism and defect the puberty. Oral vitamin D or fortified milk with vitamin D are suggested for maintain adequate level of vitamin D that has important role for calcum balance and bone growth. Thyroid drug, estrogen and testosterone supplementation is a safe for thalassemia patients have each types of endocrine disorders.
Keywords
β-Thalassemia, T4, TSH, Estradiol, Testosterone and Vitamin D
References
[01] Cao, A and Galanello, R. (2010): Beta-thalassemia. Genetics in Medicine; 12: 61-76.
[02] Cao, A and Kan, Y. W. (2013): The Prevention of Thalassemia. Cold Spring Harb Perspect Med.; 3 (2): a011775. doi: 10.1101/cshperspect.a011775.
[03] Weatherall, D. J and Clegg, J. B. (2001): The Thalassemia syndromes, 4th ed. United Kingdom: Blackwell Science.
[04] Al-Samarrai, A. H; Adaay, M. H; Al-Tikriti, K. A; Al-Anzy, M. M. (2008): Evaluation of some essential element levels in thalassemia major patients in Mosul district, Iraq. Saudi Med J; 29: 94-97.
[05] Abdulzahraa, M. S; Al-Hakeim, H. K and Ridha, M. M. (2011): Study of the effect of iron overload on the function of endocrine glands in male thalassemia patients: Asian J Trans Sci.; 5: 127-131.
[06] Al-Hakeim, H. K. Al-Khakani, M. M and Al-Kindi, M. A. (2015): Correlation of Hepcidin Level with Insulin Resistance and Endocrine Glands Function in Major Thalassemia. Adv Clin Exp Med.; 24 (1): 69-78.
[07] Mahdi, E. A. (2014): Relationship between Oxidative Stress and Antioxidant Status In Beta Thalassemia Major Patients. Acta Chim. Pharm. Indica.; 4 (3): 137-145.
[08] Telfer, P. T; Warburton, F; Christou, S; Hadjigavriel, M; Sitarou, M and Kolnagou, A. (2009): Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica.; 94 (12): 1777-8.
[09] Bhat, A. A; Parwani, R. Nand Wanjari, S. P. (2013): Demonstration of iron in exfoliated buccal cells of β-thalassemia major patients. J Cytol.; 30 (3): 169-173.
[10] Sagare, A. A and Trivedi, D. J. (2014). Assesment of Transferrin Saturation as an Indicator of Iron Overload in Homozygous & Hetrozygous Form of Thalassemia. Research Journal of Pharmaceutical, Biological and Chemical Sciences; 5 (1): 669-673.
[11] Borgna-Pignatti, C and Galanello, R. (2004): Thalassemia and related disorders: quantitative disorders of hemoglobin synthesis. In introbe's Clinical Hematology, eleven th edition. Lippincott Williams & Wilkins. Philadelphia; 1319-65.
[12] Galanello, R and Origa, R. (2010): Beta-thalassemia. Orphanet J Rare Dis.; 5: 11.
[13] De Sanctis, V; Eleftheriou, A and Malaventura, C. (2004): Prevalence of endocrine complications and short stature in patients with thalassemia major: a multicenter study by the Thalassemia International Federation (TIF). Pediatr Endocrinol Rev.; 2: 249-55.
[14] Soliman, A; Al Yafei, F; Al-Naimi, L; Almarri, N; Sabt, A and Yassin M, et al. (2013): Study on linear growth and thyroid function for 12 years in patients with β thalassemia major. Endocrine; 32: 992.
[15] Tiosano. D and Hochberg, Z. (2001): Endocrine Complications of Thalassemia. Journal of Endocrinological Investigation; 24: 716-723.
[16] Merchant, R. H; Shirodkar, A and Ahmed J. (2011): Evaluation of growth, puberty and endocrine dysfunctions in relation to ironoverload in multi transfused Indian thalassemia patients. Indian J Pediatr.; 78 (6): 679-83.
[17] Sharaf, A. E. A; Ali, S. H. and Abo-Elwafa, H. A. (2014) Evaluation of puberty in relation to iron overload in multi transfused B-thalassemia patients. Journal of American Science; 10 (11): 1-7.
[18] Kyriakou, A and Skordis, N. (2009): Thalassaemia and aberrations of growth and puberty. Mediterr J Hematol Infect Dis.; 1: e2009003.
[19] Saffari, F; Mahyar, A and Jalilolgadr, S. (2012): Endocrine and metabolic disorders in β-thalassemiamajor patients. Caspian J Intern Med.; 3 (3): 466-472.
[20] Soliman, A; De Sanctis, Vand Yassin. M. (2013): Vitamin D Status in Thalassemia Major: an Update. Mediterr J Hematol Infect Dis.; 5 (1): e2013057.
[21] Fahim, F. M; Saad, K; Askar, E. A; Eldin, E. N and Thabet, A. F. (2013): Growth parameters and vitamin D status in children with thalassemia major in upper Egypt. International Journal of Hematology-Oncology and Stem Cell Research; 7 (4): 10-14.
[22] DeLuca, H. F. (2004): Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr.; 80: 1689S-1696S.
[23] Bouillon, R. (2001): Vitamin D: from photosynthesis, metabolism, and action to clinical applications Endocrinology. Edited by: DeGroot, L. J, Jameson, J. L. Philadelphia: W. B. Saunders, 1009-1028.
[24] Holick, M. F and Garabedian, M. (2006): Vitamin D: photobiology, metabolism, mechanism of action and clinical applications. Primer on the metabolic bone diseases and disorders of mineral metabolism. Edited by: Favus MJ. Washington, DC: American Society for Bone and Mineral Research, 129: 137-6.
[25] Casey, C. F; Slawson, D. C and Neal, L. R. (2010): Vitamin D Supplementation in Infants, Children, and Adolescents. Am Fam Physician.; 81 (6): 745-748.
[26] Zittermann, A. (2003): Vitamin D in preventive medicine: are weignoring the evidence? Br J Nutr.; 89 (5): 552-72.
[27] Holick, M. F. (2009): Vitamin D Status: Measurement, Interpretation And Clinical Application. Ann Epidemiol.; 19 (2): 73-78.
[28] Berkovitch, M; Bistritzer, T; Milone, S. D; Perlman, K; Kucharczyk, W and Olivieri, N. F. (2000): Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab.; 13 (2): 179-84.
[29] Jain, M; Sinha, R. S; Chellani, H and Anand; N. K. (1995): Assessment of thyroid functions and its role in body growth in thalassemia major. Indian pediatr.; 32 (2): 213-9. PMID: 8635784.
[30] Salih, K. M and Al-Mosawy, W. F. (2013): Evaluation Some Consequences Of Thalassemia Major In Splenectomized And Non-Splenectomized Iraqi Patient. Int J Pharm Pharm Sci.; 5 (4): 385-388.
[31] Asad, Z. T; Ghazanfari, M; Naleini, S. N; Sabagh, A and Kooti, W. (2016): Evaluation of serum levels in T3, T4 and TSH in beta-thalassemic patients referred to the Abuzar hospital in Ahwaz. Electron Physician; 8 (7): 2620-4.
[32] Malik, S. A; Syed, S and Ahmed, N. (2010): Frequency of hypothyroidism in patients of beta-thalassemia. J Pak Med Assoc.; 60 (1): 17-29.
[33] Mula-Abed, W; Al-Hashimi, H; Al-Muslahi, M; Al-Muslahi, H and Al-Lamki M., (2008). Prevalence of Endocrinopathies in patients with beta-thalassemia major a cross-sectional study in Oman. Oman Med.; J. 23 (4): 257-261.
[34] Pirinccioglu, A; Deniz, T; Gokalp, D; Beyazit, N; Haspolat, K and Soker, M. (2011). Assessment of thyroid function in children aged 1 – 13 years with beta – thalassemia major. Iran J. pediatr.; 21 (1) 77-82.
[35] Ayoub, N; Khaleel, K. J and Mohammed, I. I (2016): Hypothyroidism in transfusion dependent β-thalassemia; 9 (1): 36-39.
[36] Ghosh, S; Bandyopadhyay, S. K; Bandyopadhyay, R; Roy, D; Maisnam, I and Ghosh, M. K. (2008): A study on endocrine dysfunction in thalassaemia. J Indian Med Assoc.; 106 (10): 655-6, 658-9.
[37] Soliman, A; Al Yafei, F; Al-Naimi, L; Almarri, N; Sabt, A; Yassin, M, et al. (2013): Study on linear growth and thyroid function for 12 years in patients with β thalassemia major. Endocrine; 32: 992.
[38] Aydinok, Y; Darcan, S; Polat, A; Kavakli, K; Nigli, G; Coker, M; Kantar, M and Cetingul, N. (2002): Endocrine complications in patients with b-thalassemia major. Journal of Tropical Pediatrics; 48: 50-54.
[39] Zervas, A; Katopodi, A; Protonotariou, A; Livadas, S; Karagiora M, Politis C and Tolis, G. (2002): Assessment of thyroid function in two hundred patients with β-thalassemia major. Thyroid; 12: 151-154.
[40] Fung, E; Harmatz, P. R and Lee, P. D, et al. (2006): Increased prevalence of iron overload associated endocrinopathy in thalassaemia versus sickle cell disease. Br J Haematol.; 135 (4): 574-82.
[41] Shizukuda, Y; Bolan, C. D and Nguyen, T, et al. (2007): Oxidative stress in asymptomatic subjects with hereditary hemochromatosis. Am J Hematol.; 82: 249-250.
[42] Lekawanvijit, S & Chattipakorn, N. (2009): Iron overload thalassemic cardiomyopathy: Iron status assessment and mechanisms of mechanical and electrical disturbance due to iron toxicity. Can J Cardiol.; 25 (4): 213-218.
[43] Hershko, C. (2010): Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci.; 1202: 1-9.
[44] Moayeri H and Oloomi Z. (2006). Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med.; 9 (4): 329-34.
[45] Dundar, U; Kupesiz, A; Ozdem, S; Gilgil, E; Tuncer, T; Yesilipek, A and Gultekin, M. (2007): Bone metabolism and mineral density in patients with beta-thalassemia major. Saudi Med J.; 28 (9): 1425-9.
[46] Carmina, E; Di Fede, G; Napoli, N; Renda, G; Vitale, G; Lo, P. C; Bruno, D; Malizia, R and Rini, G. B. (2004): Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int.; 74 (1): 68-71.
[47] Hegazi, M. A. M; Obada, M. A and Elsheashaey, A. M. (2013): Effect of Iron Overload on Function of Endocrine Glands in Egyptian Beta Thalassemia Patients. Journal of Applied Sciences Research, 9 (8): 4656-4662.
[48] Au, W. Y; Lam W. W; Chu, W. W; Yuen, H. L, Ling, A. S; Li RC, et al. (2009): A crosssectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassaemia major patients in Hong Kong. Haematologica; 93: 784-6.
[49] Noetzli, L. J; Panigrahy, A; Mittelman S. D; Hyderi, A; Dongelyan, A; Coates TD, et al. (2012): Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol.; 87: 167-71.
[50] Roussou, P; Tsagarakis, N. J; Kountouras, D; Livadas, S and Diamanti-Kandarakis E. (2013): Beta-thalassemia major and female fertility: the role of iron and iron induced oxidative stress. Anemia; 2013: 617204.
[51] Toumba, M and Skordis, N. (2010): Osteoporosis Syndrome in Thalassaemia Major: An Overview. J Osteoporos.; 2010: 537673. Article ID 537673, 7 pages http://dx.doi.org/10.4061/2010/537673.
[52] Lips, P; Hosking, D; Lippuner, K; Norquist, J. M; Wehren, L and Maalouf, G, et al. (2006): The prevalence of vitamin D inadequacy amongst women with osteoporosis: An international epidemiological investigation. J Intern Med.; 260: 245-54.
[53] Lappe, J. M; Travers-Gustafson, D; Davies, K. M; Recker, R. R and Heaney, R. P. (2007): Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr.; 85: 1586–91.
[54] Dandona, P; Menon, R. K; Houlder, S; Thomas, M; Hoffbrand, A. V and Flynn, D. M. (1987): Serum 1,25 dihydroxy vitamin D and osteocalcin concentrations in thalassemia major. Archives of disease in childhood; 62 (5): 474-7.
[55] Napoli, N; Carmina, E; Bucchieri, S; Sferrazza, C. Rini, G. B and Di Fede, G. (2006): Low serum levels of 25-hydroxy vitamin D in adults affected by thalassemia major or intermedia. Bone; 38 (6): 888-92.
[56] Shamsiraz, A; Bekheirnia, M. R; Kamgar, M; Pourzahedgilani, N; Bouzari, N; Habibzadeh, M, et al. (2003). Metabolic and endocrinological complications in beta- thalassaemia major: a multicenter study in Tehran. BMC Endocrine Disorders; 3: 23-34.
[57] Vogiatzi, M. G; Macklin, E. A; Trachtenberg, F. L; Fung, E. B; Cheung, A. M; Vichinsky E, et al. (2009): Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. British Journal of Haematology; 146: 546-56.
[58] Sultan, S; Irfan, S. M and Ahmed, S I. (2016): Biochemical Markers of Bone Turnover in Patients with β-Thalassemia Major: A Single Center Study from Southern Pakistan. AdvHematol.; 5437609. doi: 10.1155/2016/54376093.
[59] Soliman, A; Adel, A; Wagdy, M; AlAli, M and El Mulla, N. (2008): Calcium homeostasis in 40 adolescents with beta- thalassemia major: a case-control study of the effects of intramuscular injection of a megadose of cholecalciferol. Pediatric Endocrinology Reviews; 6: 149-54.
[60] Merchant, R; Udani, A; Puri, V; D'cruz, V; Patkar; D and Karkera A. (2010): Evaluation of osteopathy in thalassemia by bone mineral densitometry and biochemical indices. Indian J Pediatr.; 77 (9): 987-91. doi: 10.1007/s 12098-010-0158-2.
[61] Fung, E; Aguilar, C; Micaily, I; Haines, D and Lal, A. (2011): Treatment of vitamin D deficiency in transfusion-dependent thalassemia. Am J Hematol.; 86: 871-3.
[62] Agrawal, A; Garg, M; Singh, J; Mathur, P and Khan, K. (2016): A comparative study of 25 hydroxy vitamin D levels in patients of thalassemia and healthy children. Pediatric Review: International Journal of Pediatric Research; 3 (9): 652-656.
[63] Pirinççioğlu, A. G; Akpolat, V; Köksal, O; Haspolat, K and Söker, M. (2011): Bone mineral density in children with beta-thalassemia major in Diyarbakir,” Bone, vol. 49 (4): 819-823.
[64] Ezzat, H. M; John Wu, J; McCartney. H and Leitch, H. A. (2015): Vitamin D Insufficiency and Liver Iron Concentration in Transfusion Dependent Hemoglobinopathies in British Columbia. Open Journal of Hematology, 6-6 DOI: 10.13055/ojhmt_6_1_6.150608.
[65] Malik, S; Syed, S and Ahmed N. (2009): Complications in transfusion-dependent patients of β- thalassaemia major: A review. Pakistan Journal of Medical Sciences; 25: 678-82.
600 ATLANTIC AVE, BOSTON,
MA 02210, USA
+001-6179630233
AIS is an academia-oriented and non-commercial institute aiming at providing users with a way to quickly and easily get the academic and scientific information.
Copyright © 2014 - 2017 American Institute of Science except certain content provided by third parties.